CFS
VRTX icon

CGC Financial Services’s Vertex Pharmaceuticals VRTX Stock Holding History

CGC Financial Services’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$392 – 352
2025
Q3 		$392 Hold
1
– – ﹤0.01% 326
2025
Q2 		$445 Hold
1
– – ﹤0.01% 314
2025
Q1 		$485 Hold
1
– – ﹤0.01% 310
2024
Q4 		$403 Hold
1
– – ﹤0.01% 324
2024
Q3 		$465 Hold
1
– – ﹤0.01% 316
2024
Q2 		$469 Hold
1
– – ﹤0.01% 318
2024
Q1 		$418 Buy
+1
New +$423 ﹤0.01% 330

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

CGC Financial Services's VRTX Position: Q4 2025 in Review

CGC Financial Services sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 1 share — an estimated $392 sold.

CGC Financial Services first reported a position in VRTX in Q1 2024 and held it in 7 quarters. The position peaked at $485 in Q1 2025. 1,674 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • CGC Financial Services reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • CGC Financial Services sold 1 Vertex Pharmaceuticals share in Q4 2025, an estimated $392.
  • CGC Financial Services first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 7 quarters.
  • CGC Financial Services's Vertex Pharmaceuticals position peaked at $485 in Q1 2025.
  • 1,674 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on CGC Financial Services's 13F filing for Q4 2025, filed 3 Feb 2026.